AA
TVRD

ALPS Advisors’s Tvardi Therapeutics TVRD Stock Holding History

ALPS Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-987
Closed -$175K – 1036
2023
Q1 		$175K Sell
987
-26
-3% -$8.71K ﹤0.01% 988
2022
Q4 		$391K Buy
+1,013
New +$385K ﹤0.01% 685
2019
Q4 		– Sell
-2,579
Closed -$1.7M – 866
2019
Q3 		$1.7M Buy
2,579
+268
+12% +$223K 0.01% 230
2019
Q2 		$1.79M Sell
2,311
-336
-13% -$236K 0.01% 239
2019
Q1 		$1.87M Buy
2,647
+115
+5% +$68.8K 0.01% 230
2018
Q4 		$1.19M Buy
+2,532
New +$1.63M 0.01% 273
2016
Q2 		– Sell
-851
Closed -$190K – 638
2016
Q1 		$190K Sell
851
-145
-15% -$43.3K ﹤0.01% 606
2015
Q4 		$605K Sell
996
-160
-14% -$87.8K 0.01% 269
2015
Q3 		$5.95K Buy
1,156
+528
+84% +$353K 0.01% 241
2015
Q2 		$275K Buy
628
+314
+100% +$121K ﹤0.01% 661
2015
Q1 		$114K Buy
+314
New +$119K ﹤0.01% 653

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ALPS Advisors's TVRD Position: Q2 2023 in Review

ALPS Advisors sold out of Tvardi Therapeutics (TVRD) in Q2 2023, closing a stake of 987 shares — an estimated $175K sold.

ALPS Advisors first reported a position in TVRD in Q1 2015 and held it in 11 quarters. The position peaked at $1.87M in Q1 2019. 136 funds tracked by Wall St. Rank hold TVRD as of Q2 2023.

  • ALPS Advisors reported no remaining Tvardi Therapeutics position as of Q2 2023 after selling out during the quarter.
  • ALPS Advisors sold 987 Tvardi Therapeutics shares in Q2 2023, an estimated $175K.
  • ALPS Advisors first reported a position in Tvardi Therapeutics in Q1 2015 and held it in 11 quarters.
  • ALPS Advisors's Tvardi Therapeutics position peaked at $1.87M in Q1 2019.
  • 136 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2023.

Based on ALPS Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.